How to Submit Written Testimony for the SRP-9001 FDA Advisory Committee Meeting – Deadline May 5th
Sarepta recently announced that the FDA Advisory Committee meeting for SRP-9001 (delandistrogene moxeparvovec), Sarepta’s investigational gene therapy for Duchenne muscular dystrophy, will be held on May 12th. The event will be completely virtual and a…Learn More